论文-万方医学网

1. ?Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study

【外文期刊】 Lukas,K?smann ; Chukwuka,Eze ; 等《Journal of Cancer Research and Clinical Oncology》 2023年149卷10期 7393-7403页 SCISCIEMEDLINE

【关键词】 NSCLC; Durvalumab; Nivolumab;

原文传递

浏览：0 被引：0 下载：0

2. Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.

【外文期刊】 Lukas,Käsmann ; Chukwuka,Eze ; 等《Journal of cancer research and clinical oncology》 2023年149卷10期 7393-7403页 SCIMEDLINEBP

【关键词】 Chemoradiation; Durvalumab; NSCLC;

OA

浏览：0 被引：0 下载：0

3. Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.

【外文期刊】 Chukwuka,Eze ; Julian Elias,Guggenberger ; 等《Cancer》 2022年128卷12期 2358-2366页 SCIMEDLINEBP

【关键词】 hypofractionation; image-guided radiotherapy; non-small cell lung cancer (NSCLC);

原文传递

浏览：0 被引：0 下载：0

4. Dosimetric Predictors of Acute Radiation Pneumonitis and Esophagitis in Hypofractionated Thoracic Irradiation of Non-Small Cell Lung Cancer Patients With Poor Prognostic Factors.

【外文期刊】 Saskia,Kenndoff ; Alexander,Nieto ; 等《Advances in radiation oncology》 2025年10卷2期 101682页

LinkOut

浏览：0 被引：0 下载：0

5. NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer.

【外文期刊】 Farkhad,Manapov ; Saskia,Kenndoff ; 等《Translational lung cancer research》 2022年11卷4期 702-705页

LinkOut

浏览：0 被引：0 下载：0

6. Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study.

【外文期刊】 Lukas,Käsmann ; Julian,Taugner ; 等《Translational lung cancer research》 2022年11卷7期 1503-1509页

【关键词】 Chemoradiotherapy (CRT); biomarker; immunotherapy;

LinkOut

浏览：0 被引：0 下载：0

7. Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports.

【外文期刊】 Farkhad,Manapov ; Alexander,Nieto ; 等《Expert opinion on investigational drugs》 2023年32卷3期 187-200页 SCIMEDLINECABP

【关键词】 Checkpoint inhibition; PD-L1; durvalumab;

LinkOut

浏览：0 被引：0 下载：0

8. Prognostic significance of pretreatment PET parameters in inoperable, node-positive NSCLC patients with poor prognostic factors undergoing hypofractionated radiotherapy: a single-institution retrospective study.

【外文期刊】 Annemarie Barbara,Zinn ; Saskia,Kenndoff ; 等《EJNMMI reports》 2024年8卷1期 32页

【关键词】 Baseline PET; Hypofractionation; NSCLC;

LinkOut

浏览：0 被引：0 下载：0

9. Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports

【外文期刊】 Manapov, Farkhad ; Nieto, Alexander ; 等《Expert opinion on investigational drugs》 2023年32卷1/6期 187-200页 SCISCIEMEDLINE

【关键词】 Checkpoint inhibition; durvalumab; interferon gamma;

原文传递

浏览：0 被引：0 下载：0

检索历史清除

模糊

与

模糊

与

模糊

开始

结束

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

模糊

与

模糊

与

模糊

开始

结束

批量导出

批量导出

检索历史清除